CN100360931C - A kind of quality control method of salvia miltiorrhiza and notoginseng preparation - Google Patents
A kind of quality control method of salvia miltiorrhiza and notoginseng preparation Download PDFInfo
- Publication number
- CN100360931C CN100360931C CNB2005100951807A CN200510095180A CN100360931C CN 100360931 C CN100360931 C CN 100360931C CN B2005100951807 A CNB2005100951807 A CN B2005100951807A CN 200510095180 A CN200510095180 A CN 200510095180A CN 100360931 C CN100360931 C CN 100360931C
- Authority
- CN
- China
- Prior art keywords
- finger
- add
- preparation
- notoginseng
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 40
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 238000003908 quality control method Methods 0.000 title abstract description 8
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 title description 23
- 241000304195 Salvia miltiorrhiza Species 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 22
- 240000007164 Salvia officinalis Species 0.000 claims abstract 5
- 235000005412 red sage Nutrition 0.000 claims abstract 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000010828 elution Methods 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 13
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 6
- 238000002137 ultrasound extraction Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims 2
- 238000010586 diagram Methods 0.000 claims 2
- 238000007654 immersion Methods 0.000 claims 2
- 238000010298 pulverizing process Methods 0.000 claims 2
- IAWPVNMEXASPFO-UHFFFAOYSA-N C(CCCCCCCCCCCCCCCCC)[SiH3].[C] Chemical compound C(CCCCCCCCCCCCCCCCC)[SiH3].[C] IAWPVNMEXASPFO-UHFFFAOYSA-N 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 244000132619 red sage Species 0.000 abstract description 56
- 150000001875 compounds Chemical class 0.000 abstract description 40
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract description 34
- 239000006187 pill Substances 0.000 abstract description 13
- 239000009524 danshen dripping Substances 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000012085 test solution Substances 0.000 description 29
- 238000004587 chromatography analysis Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 3
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- -1 diterpene quinones Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960003371 protocatechualdehyde Drugs 0.000 description 3
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 3
- 239000008678 sanqi Substances 0.000 description 3
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 2
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LLPWNQMSUYAGQI-QBQUQATFSA-N Ginsenoside R1 Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 LLPWNQMSUYAGQI-QBQUQATFSA-N 0.000 description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- LLPWNQMSUYAGQI-OOSPGMBYSA-N notoginsenoside R1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LLPWNQMSUYAGQI-OOSPGMBYSA-N 0.000 description 2
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 229930183842 salvianolic acid Natural products 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
技术领域:Technical field:
本发明涉及天然药物的质量控制领域,具体为指纹图谱领域,具体涉及丹参和三七复方的HPLC-DAD指纹图谱鉴定方法。其可作为含有丹参和三七药材的复方制剂质量控制的指标之一。The invention relates to the field of quality control of natural medicines, in particular to the field of fingerprints, in particular to an HPLC-DAD fingerprint identification method of Danshen and Panax notoginseng compound prescriptions. It can be used as one of the indicators for the quality control of compound preparations containing Danshen and Panax notoginseng.
背景技术:Background technique:
含有丹参和三七的制剂,通常亦被称为复方丹参制剂,在临床上广泛用于治疗心血管疾病。常见的有复方丹参片,复方丹参滴丸,丹七片,冠心丹参片等。Preparations containing Danshen and Panax notoginseng, commonly known as compound Danshen preparations, are widely used clinically to treat cardiovascular diseases. The common ones are Compound Danshen Tablets, Compound Danshen Dripping Pills, Danqi Tablets, Guanxin Danshen Tablets, etc.
丹参和三七是复方丹参制剂的两个主要组成药物,其中丹参为唇形科植物丹参Salvia miltiorrhiza Bge.的干燥根,具祛瘀止痛,活血通经,清心除烦之功效,用于月经不调,经闭痛经,癥瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠,肝脾肿大,心绞痛;三七为五加科植物三七Panax notoginseng(Burk.)F.H.Chen的干燥根,具散瘀止血,消肿定痛之功效。用于咯血,吐血,衄血,外伤出血,跌扑肿痛等症。Salvia miltiorrhiza and Panax notoginseng are the two main components of compound salvia miltiorrhiza preparations. Salvia miltiorrhiza is the dry root of Salvia miltiorrhiza Bge., a plant of the Labiatae family. Tune, amenorrhea, dysmenorrhea, accumulation of lumps in the abdomen, tingling pain in the chest and abdomen, heat arthralgia pain, sore swelling and pain, upset and insomnia, hepatosplenomegaly, angina pectoris; Panax notoginseng is the Araliaceae plant Panax notoginseng (Burk.) F.H. The dried root of Chen has the effects of dispelling blood stasis and hemostasis, reducing swelling and relieving pain. For hemoptysis, hematemesis, epistaxis, traumatic hemorrhage, tumbling, swelling and pain embolisms.
现代研究表明丹参的活性成分主要为二萜醌类脂溶性及丹参酚酸类水溶性有效成分,丹参酚酸类成分具抑制血小板聚集,抗血栓形成,抗氧化及保护心脏微血管内皮细胞等作用;丹参酮等脂溶性成分能扩张冠状动脉,提高冠脉血流,保护心肌及广谱抑菌作用。三七皂苷类成分是三七的主要活性成分,具抗血栓形成,扩张血管及保护心肌等作用。Modern research shows that the active ingredients of Salvia miltiorrhiza are mainly fat-soluble diterpene quinones and water-soluble active ingredients of salvianolic acids, which have the functions of inhibiting platelet aggregation, antithrombotic formation, anti-oxidation and protecting cardiac microvascular endothelial cells; Fat-soluble components such as tanshinone can expand coronary arteries, improve coronary blood flow, protect myocardium and have broad-spectrum antibacterial effects. Panax notoginseng saponins are the main active ingredients of Panax notoginseng, which have anti-thrombosis, dilating blood vessels and protecting myocardium.
目前关于丹参和三七复方制剂指纹图谱鉴定方法的研究报导,大多为丹参或三七单味药材的鉴定,如丹参药材乙醇提取物高效液相色谱指纹图谱研究(中国药学杂志2004年8月第39卷第8期)、三七指纹图谱研究(Strait PharmaceuticalJournal Vol 14 No52002)。现有技术未能用指纹图谱同时鉴定丹参和三七两味药中多类活性成分。At present, most of the research reports about the fingerprint identification method of Danshen and Sanqi compound preparations are the identification of Danshen or Sanqi single medicinal material, such as the research on high performance liquid chromatography fingerprint of Danshen medicinal material ethanol extract (Chinese Journal of Pharmaceutical Sciences, August 2004, No. Volume 39, No. 8), research on fingerprints of Panax notoginseng (Strait Pharmaceutical Journal
发明内容:Invention content:
本发明的目的在于建立一种能够同时鉴定丹参和三七复方中丹参与三七两味药中多类活性成分的指纹图谱。The purpose of the present invention is to establish a fingerprint that can simultaneously identify multiple types of active ingredients in Danshen and Sanqi compound prescriptions.
本发明的另一目的在于将本发明的指纹图谱用于含有丹参和三七药材的复方制剂的质量控制。Another object of the present invention is to apply the fingerprint of the present invention to the quality control of the compound preparation containing Danshen and Panax notoginseng.
本发明是这样实现的:The present invention is achieved like this:
我们模拟了丹七片的处方(以下称为丹七方),通过对丹七方供试液制备方法,色谱条件选择及色谱条件方法学研究,确定了丹七方HPLC-DAD指纹图谱。该指纹图谱可满足对丹七方中丹参和三七的多类活性成分的同时检测与分析。我们又进一步将此指纹图谱用于含有丹参和三七药材的复方制剂质量控制。We simulated the prescription of Danqi Tablets (hereinafter referred to as Danqifang), and determined the HPLC-DAD fingerprint of Danqifang by studying the preparation method of Danqifang's test solution, the selection of chromatographic conditions and the methodology of chromatographic conditions. The fingerprint can meet the simultaneous detection and analysis of multiple types of active ingredients in Danshen and Panax notoginseng in Danqi prescription. We further used this fingerprint for the quality control of compound preparations containing Danshen and Panax notoginseng.
本发明的具体方案如下:Concrete scheme of the present invention is as follows:
使用高效液相色谱仪,DAD检测器,色谱工作站,将丹参和三七复方溶液,采用如下色谱条件:Using a high-performance liquid chromatograph, a DAD detector, and a chromatographic workstation, the compound solution of Salvia Miltiorrhiza and Radix Notoginseng was adopted with the following chromatographic conditions:
色谱柱:碳十八烷基键合硅胶填料色谱柱和预柱;Chromatographic column: carbon octadecyl bonded silica gel packing column and pre-column;
柱温:25-35℃;Column temperature: 25-35°C;
流动相:A为0.1-0.5%的磷酸水;B为乙腈;A+B=100%,采用梯度洗脱:0-10min,7-17%B,10-12min,17-20%B,12-16min,20-21%B,16-32min,21%B,32-40min,21-29%B,40-55min,29-35%B,55-65min,35-70%B,65-75min,70-80%B,75-80min,80-97%B,80-82min,97-100%B,82-85min,100%B;或者在55分钟后梯度为:55-65min,35-65%B,65-80min,65-80%B,80-85min,80-100%B;Mobile phase: A is 0.1-0.5% phosphoric acid water; B is acetonitrile; A+B=100%, using gradient elution: 0-10min, 7-17%B, 10-12min, 17-20%B, 12 -16min, 20-21%B, 16-32min, 21%B, 32-40min, 21-29%B, 40-55min, 29-35%B, 55-65min, 35-70%B, 65-75min , 70-80% B, 75-80min, 80-97% B, 80-82min, 97-100% B, 82-85min, 100% B; or after 55 minutes the gradient is: 55-65min, 35-65 %B, 65-80min, 65-80%B, 80-85min, 80-100%B;
流速:1ml/min,在22~28分钟时,流速为0.8ml/min;Flow rate: 1ml/min, at 22-28 minutes, the flow rate is 0.8ml/min;
检测波长203,281nm。The detection wavelength is 203, 281nm.
优选的柱温是30℃。The preferred column temperature is 30°C.
优选的磷酸水的浓度为0.1%,为体积百分比。The preferred concentration of phosphoric acid water is 0.1%, which is volume percentage.
供试品溶液的制备方法是:取粉碎的丹参和三七,加入85-95%乙醇浸泡,水浴回流提取,放冷,滤过;药渣加水煎煮,放冷,滤过,合并滤液,浓缩至近干,加50-90%甲醇溶解,定容。The preparation method of the test solution is: take the pulverized Salvia miltiorrhiza and Notoginseng, add 85-95% ethanol to soak, extract in a water bath under reflux, let cool, and filter; Concentrate to near dryness, add 50-90% methanol to dissolve, and constant volume.
优选的制备方法是:取粉碎的同样份数的丹参和三七,加入6-12倍重量份数的90%乙醇浸泡,水浴回流提取,放冷,滤过;药渣加水煮,加水量是药材重量的10-30倍,放冷,滤过,合并滤液,于50℃减压浓缩至近干,加70%甲醇溶解,定容。The preferred preparation method is as follows: take crushed salvia miltiorrhiza and Panax notoginseng in the same number, add 6-12 times the weight parts of 90% ethanol to soak, water bath reflux extraction, let cool, filter; 10-30 times the weight of the medicinal materials, let cool, filter, combine the filtrates, concentrate under reduced pressure at 50°C until nearly dry, add 70% methanol to dissolve, and constant volume.
上述液相色谱仪进样量优选10μl。The injection volume of the above-mentioned liquid chromatograph is preferably 10 μl.
本发明的指纹图谱鉴定方法,记录时间在85分钟即可,用于鉴定丹七片,复方丹参滴丸时记录时间为55-65分钟即可。The fingerprint identification method of the present invention needs a recording time of 85 minutes, which is 55-65 minutes for identifying Danqi Tablets and Compound Danshen Dripping Pills.
下面是本发明的部分试验:Below is the part test of the present invention:
1.供试品溶液的制备:取粉碎的丹参和三七适量,加入90%乙醇,浸泡,水浴回流提取2h,放冷,滤过;药渣加适量水继续煎煮2h,滤过,合并滤液,减压回收乙醇至干,加70%甲醇溶解并转移至容量瓶定容至刻度,微孔滤膜过滤,得供试品溶液(0.024g生药/ml)。进样10μl进行色谱分析。1. Preparation of the test solution: Take an appropriate amount of crushed Salvia miltiorrhiza and Panax notoginseng, add 90% ethanol, soak, reflux in a water bath to extract for 2 hours, let cool, and filter; add appropriate amount of water to the dregs and continue to decoct for 2 hours, filter, and combine Filtrate, reclaim ethanol under reduced pressure to dryness, add 70% methanol to dissolve and transfer to volumetric flask and constant volume to mark, filter with microporous membrane, obtain need testing solution (0.024g crude drug/ml). Inject 10 μl for chromatographic analysis.
2.HPLC色谱分析条件:2. HPLC chromatographic analysis conditions:
色谱柱:碳十八烷基键合硅胶填料色谱柱(4.6×250mm ID,5μm)和预柱(4.6×12.5mmID,5μm);柱温:30℃;流动相,A为0.1%的磷酸水;B为乙腈;A+B=100%,采用梯度洗脱:0-10min,7-17%B,10-12min,17-20%B,12-16min,20-21%B,16-32min,21%B,32-40min,21-29%B,40-55min,29-35%B,55-65min,35-70%B,65-75min,70-80%B,75-80min,80-97%B,80-82min,97-100%B,82-85min,100%B;或者在55分钟后梯度为:55-65min,35-65%B,65-80min,65-80%B,80-85min,80-100%B。流速:1ml/min(22-28min,0.8ml/min);检测波长203,281nm。记录时间85min。Chromatographic column: carbon octadecyl bonded silica gel column (4.6×250mm ID, 5μm) and pre-column (4.6×12.5mmID, 5μm); column temperature: 30°C; mobile phase, A is 0.1% phosphoric acid water ; B is acetonitrile; A+B=100%, gradient elution: 0-10min, 7-17%B, 10-12min, 17-20%B, 12-16min, 20-21%B, 16-32min , 21%B, 32-40min, 21-29%B, 40-55min, 29-35%B, 55-65min, 35-70%B, 65-75min, 70-80%B, 75-80min, 80 -97%B, 80-82min, 97-100%B, 82-85min, 100%B; or after 55min the gradient is: 55-65min, 35-65%B, 65-80min, 65-80%B , 80-85min, 80-100% B. Flow rate: 1ml/min (22-28min, 0.8ml/min); detection wavelength 203, 281nm. The recording time is 85min.
3色谱条件的选择及结果3 Selection of chromatographic conditions and results
3.1洗脱系统的选择及结果3.1 Elution system selection and results
本实验对3种流动相系统进行了选择:(1)乙腈-水梯度洗脱;(2)乙腈-0.1%-0.5%磷酸梯度洗脱;(3)乙腈-0.1%甲酸梯度洗脱。Three mobile phase systems were selected in this experiment: (1) acetonitrile-water gradient elution; (2) acetonitrile-0.1%-0.5% phosphoric acid gradient elution; (3) acetonitrile-0.1% formic acid gradient elution.
结果表明,乙腈-0.1%-0.5%磷酸梯度洗脱吸收峰数目多,峰形好,基线平稳,优于乙腈-0.1%甲酸,乙腈-水梯度洗脱系统。乙腈-0.1%-0.5%磷酸梯度洗脱效果相当,0.1%磷酸浓度较低,对色谱柱的损耗小,故更优的是乙腈-0.1%磷酸梯度洗脱。The results show that the acetonitrile-0.1%-0.5% phosphoric acid gradient elution system has more absorption peaks, better peak shape and stable baseline, which is better than acetonitrile-0.1% formic acid and acetonitrile-water gradient elution system. The gradient elution effect of acetonitrile-0.1%-0.5% phosphoric acid is equivalent, and the concentration of 0.1% phosphoric acid is lower, and the loss to the chromatographic column is small, so the gradient elution of acetonitrile-0.1% phosphoric acid is more optimal.
3.2洗脱梯度、柱温、及流速的选择及结果3.2 Selection and results of elution gradient, column temperature, and flow rate
对5个洗脱梯度,柱温(25-35℃)及流速进行考察。结果确定:Five elution gradients, column temperature (25-35°C) and flow rate were investigated. The result is OK:
洗脱梯度:0-10min,7-17%B,10-12min,17-20%B,12-16min,20-21%B,16-32min,21%B,32-40min,21-29%B,40-55min,29-35%B,55-65min,35-70%B,65-75min,70-80%B,75-80min,80-97%B,80-82min,97-100%B,82-85min,100%B(流动相A为0.1%的磷酸水;B为乙腈;A+B=100%)。或者在55分钟后梯度为:55-65min,35-65%B,65-80min,65-80%B,80-85min,80-100%B。优选的柱温:30℃Elution gradient: 0-10min, 7-17% B, 10-12min, 17-20% B, 12-16min, 20-21% B, 16-32min, 21% B, 32-40min, 21-29% B, 40-55min, 29-35% B, 55-65min, 35-70% B, 65-75min, 70-80% B, 75-80min, 80-97% B, 80-82min, 97-100% B, 82-85min, 100% B (mobile phase A is 0.1% phosphoric acid water; B is acetonitrile; A+B=100%). Or after 55 minutes the gradient is: 55-65min, 35-65%B, 65-80min, 65-80%B, 80-85min, 80-100%B. Preferred column temperature: 30°C
3.3检测波长的确定3.3 Determination of detection wavelength
丹七方提取液中三七的主要成分为三七皂苷类;丹参的主要成分为丹参酚酸类水溶性及丹参醌类脂溶性成分。根据这些成分的紫外吸收特征,设置203,254,270,281和286nm五个波长对色谱条件进行考察,结果表明三七皂苷类成分只在203nm低波长处出峰;丹参化学成分在各波长均有不同吸收,281nm比254,270和286nm能更好的兼顾丹参水溶性及脂溶性成分。综合考虑,选择203nm和281nm两个波长。The main components of Panax notoginseng in Danqifang extract are notoginseng saponins; the main components of Danshen are water-soluble salvianolic acids and lipid-soluble salvianolic quinones. According to the ultraviolet absorption characteristics of these components, five wavelengths of 203, 254, 270, 281 and 286nm were set to investigate the chromatographic conditions. There are different absorptions, 281nm is better than 254, 270 and 286nm to take into account the water-soluble and fat-soluble components of Danshen. Comprehensive consideration, choose two wavelengths of 203nm and 281nm.
3.4丹七方供试品溶液制备的方法及结果3.4 The method and result of Danqifang test product solution preparation
本试验对丹七方的工艺进行了优化,旨在使丹七方供试液能全面反映其有效成分,同时减少糖类、鞣质等杂质的干扰。In this experiment, the process of Danqifang was optimized, so that the test solution of Danqifang could fully reflect its active ingredients, and at the same time reduce the interference of impurities such as sugar and tannin.
供试液1:取粉碎的丹参0.6g,三七0.6g,加入30ml水浸泡1h,煎煮2h,放冷,滤过,滤液于50℃减压浓缩至近干,加70%甲醇溶解并转移至50ml容量瓶定容。Test solution 1: Take 0.6g of crushed salvia miltiorrhiza and 0.6g of notoginseng, add 30ml of water to soak for 1h, decoct for 2h, let cool, filter, and concentrate the filtrate at 50°C to nearly dryness under reduced pressure, add 70% methanol to dissolve and transfer Dilute to 50ml volumetric flask.
供试液2:取粉碎的丹参0.6g,三七0.6g,加入30ml水浸泡1h,煎煮2h,放冷,滤过,滤液于50℃减压浓缩至2ml,加3倍量95%乙醇醇沉,冰箱静置过液,滤过,滤液于50℃减压浓缩至近干,加70%甲醇溶解并转移至50ml容量瓶定容。Test solution 2: Take 0.6g of crushed salvia miltiorrhiza and 0.6g of notoginseng, add 30ml of water to soak for 1h, decoct for 2h, let cool, filter, concentrate the filtrate to 2ml at 50°C under reduced pressure, add 3 times the amount of 95% ethanol Precipitate with alcohol, let stand in the refrigerator to pass through the liquid, filter, concentrate the filtrate at 50°C under reduced pressure to near dryness, add 70% methanol to dissolve and transfer to a 50ml volumetric flask to constant volume.
供试液3:取粉碎的丹参0.6g,三七0.6g,加入90%乙醇10ml浸泡1h,水浴回流提取2h,放冷,滤过,滤液于50℃减压浓缩至近干,加70%甲醇溶解并转移至50ml容量瓶定容。Test solution 3: Take 0.6g of crushed salvia miltiorrhiza and 0.6g of notoginseng, add 10ml of 90% ethanol to soak for 1h, reflux in a water bath to extract for 2h, let cool, filter, and concentrate the filtrate at 50°C to nearly dryness under reduced pressure, add 70% methanol Dissolve and transfer to a 50ml volumetric flask to volume.
供试液4:取粉碎的丹参0.6g,三七0.6g,加入70%乙醇10ml浸泡1h,水浴回流提取2h,放冷,滤过,药渣继续用70%乙醇提取1次,合并滤液,滤液于50℃减压浓缩至近干,加70%甲醇溶解并转移至50ml容量瓶定容。Test solution 4: Take 0.6g of crushed salvia miltiorrhiza and 0.6g of notoginseng, add 10ml of 70% ethanol to soak for 1h, extract in a water bath for 2h under reflux, let cool, filter, continue to extract the dregs with 70% ethanol once, combine the filtrate, The filtrate was concentrated to near dryness under reduced pressure at 50°C, dissolved in 70% methanol and transferred to a 50ml volumetric flask to constant volume.
供试液5:取粉碎的丹参0.6g,三七0.6g,加入90%乙醇10ml浸泡1h,水浴回流提取2h,放冷,滤过;药渣加入50%乙醇10ml继续提取1次,合并滤液,滤液于50℃减压浓缩至近干,加70%甲醇溶解并转移至50ml容量瓶定容。Test solution 5: take 0.6g of crushed salvia miltiorrhiza and 0.6g of notoginseng, add 10ml of 90% ethanol to soak for 1h, extract in a water bath for 2h under reflux, let cool, and filter; add 10ml of 50% ethanol to the dregs to continue extracting once, and combine the filtrate , The filtrate was concentrated to near dryness under reduced pressure at 50°C, dissolved in 70% methanol and transferred to a 50ml volumetric flask to constant volume.
供试液6:取粉碎的丹参0.6g,三七0.6g,加入90%乙醇10ml浸泡1h,水浴回流提取2h,放冷,滤过;药渣加水30ml煎煮2h,放冷,滤过,滤液于50℃减压浓缩至2ml,加3倍量95%乙醇醇沉,冰箱静置过液,滤过,滤液同90%乙醇提取滤液合并,于50℃减压浓缩至近干,加70%甲醇溶解并转移至50ml容量瓶定容。Test solution 6: Take 0.6g of crushed salvia miltiorrhiza and 0.6g of notoginseng, add 10ml of 90% ethanol to soak for 1h, reflux in a water bath to extract for 2h, let cool, and filter; add 30ml of water to decoct the dregs of the medicine for 2h, let cool, filter, Concentrate the filtrate to 2ml at 50°C under reduced pressure, add 3 times the amount of 95% ethanol for ethanol precipitation, let the liquid stand in the refrigerator, filter, combine the filtrate with 90% ethanol extraction filtrate, concentrate under reduced pressure at 50°C to nearly dryness, add 70% Dissolve in methanol and transfer to a 50ml volumetric flask to volume.
供试液7:取粉碎的丹参0.6g,三七0.6g,加入90%乙醇10ml浸泡1h,水浴回流提取2h,放冷,滤过;药渣加水30ml煎煮2h,放冷,滤过,合并滤液,于50℃减压浓缩至近干,加50%甲醇溶解并转移至50ml容量瓶定容。Test solution 7: Take 0.6g of crushed salvia miltiorrhiza and 0.6g of notoginseng, add 10ml of 90% ethanol to soak for 1h, reflux in a water bath to extract for 2h, let cool, and filter; add 30ml of water to decoct the dregs of the medicine for 2h, let cool, filter, The filtrates were combined, concentrated under reduced pressure at 50°C to near dryness, dissolved in 50% methanol and transferred to a 50ml volumetric flask to constant volume.
供试液8:取粉碎的丹参0.6g,三七0.6g,加入90%乙醇10ml浸泡1h,水浴回流提取2h,放冷,滤过;药渣加水30ml煎煮2h,放冷,滤过,合并滤液,于50℃减压浓缩至近干,加60%甲醇溶解并转移至50ml容量瓶定容。Test solution 8: Take 0.6g of crushed salvia miltiorrhiza and 0.6g of notoginseng, add 10ml of 90% ethanol to soak for 1h, reflux in a water bath to extract for 2h, let cool, and filter; add 30ml of water to decoct the dregs of the medicine for 2h, let cool, filter, The filtrates were combined, concentrated under reduced pressure at 50°C to near dryness, dissolved in 60% methanol and transferred to a 50ml volumetric flask to constant volume.
供试液9:取粉碎的丹参0.6g,三七0.6g,加入90%乙醇10ml浸泡1h,水浴回流提取2h,放冷,滤过;药渣加水30ml煎煮2h,放冷,滤过,合并滤液,于50℃减压浓缩至近干,加70%甲醇溶解并转移至50ml容量瓶定容。Test solution 9: take 0.6g of crushed salvia miltiorrhiza and 0.6g of notoginseng, add 10ml of 90% ethanol to soak for 1h, extract in a water bath for 2h under reflux, let cool, and filter; add 30ml of water to decoct the dregs of the medicine for 2h, let cool, filter, The filtrates were combined, concentrated under reduced pressure at 50°C to near dryness, dissolved in 70% methanol and transferred to a 50ml volumetric flask to constant volume.
制备丹七方各供试品溶液,液相色谱仪自动进样10μl进行色谱分析。结果表明:单纯水提,70%乙醇及90%乙醇提取均不能很好的兼顾丹七方水溶性及脂溶性成分;90%乙醇与水提取相结合比90%乙醇与50%乙醇提取相结合效果好,但水提部分经醇沉对原儿茶醛略有损失,故可不经过醇沉:样品用70%甲醇溶解比用50%及60%甲醇溶解能更好的兼顾水溶性及脂溶性成分。综上,选取最优的供试液9的制备工艺。Prepare each test solution of Danqifang, and automatically inject 10 μl into the liquid chromatograph for chromatographic analysis. The results show that: simple water extraction, 70% ethanol and 90% ethanol extraction can not take into account the water-soluble and fat-soluble components of Danqi Fang; The effect is good, but the alcohol precipitation of the water extraction part has a slight loss of protocatechualdehyde, so alcohol precipitation is not necessary: the sample is dissolved in 70% methanol than 50% and 60% methanol, which can better balance water solubility and fat solubility Element. In summary, the optimal preparation process for
3.5检测方法的方法学考察3.5 Methodological investigation of detection methods
3.5.1供试品溶液稳定性及仪器精密度实验3.5.1 The test solution stability and instrument precision experiment
按“1”项下方法制备丹七方供试品溶液,分别在0、2、4、12、18、24小时检测指纹图谱(见图1-1,1-2),考察丹七方供试品溶液的稳定性以及高效液相色谱仪的精密度。结果表明丹七方供试液在24小时内稳定,高效液相色谱仪的精密度也符合要求。Prepare the Danqifang test product solution according to the method under "1", and detect the fingerprints at 0, 2, 4, 12, 18, and 24 hours respectively (see Figure 1-1, 1-2), and investigate the Danqifang for The stability of the test solution and the precision of the high performance liquid chromatography. The results showed that the test solution of Danqifang was stable within 24 hours, and the precision of the high performance liquid chromatography also met the requirements.
3.5.2供试品溶液测定的重复性实验3.5.2 Repeatability experiment for the determination of the test solution
取同一批丹参及三七药材粗粉(40目),按“1”项下方法平行制备3份丹七方供试溶液,检测HPLC指纹图谱(见图2-1,2-2),考察丹七方的提取方法及指纹图谱检测方法的稳定性和重复性。结果表明丹七方供试液制备方法稳定可靠,具有很好的重现性。Take the same batch of Danshen and Panax notoginseng crude powder (40 mesh), prepare 3 parts of Danqifang test solutions in parallel according to the method under "1", detect the HPLC fingerprints (see Figure 2-1, 2-2), and investigate The extraction method of Danqifang and the stability and repeatability of the fingerprint detection method. The results showed that the preparation method of Danqifang test solution was stable and reliable, with good reproducibility.
3.5.3记录时间的确定3.5.3 Determination of recording time
丹七方供试液在“2”项色谱条件下的2小时记录图和空白对照图(见图3-1,3-2),考察最佳记录时间。结果表明,80min以后基本无样品中的成分,因而确定最佳记录时间为85min。The 2-hour record chart and the blank control chart (see Figure 3-1, 3-2) of the Danqifang test solution under the chromatographic condition of item "2" are used to investigate the best record time. The results show that after 80 minutes, there is basically no component in the sample, so the best recording time is determined to be 85 minutes.
3.5.4标准品对照实验:3.5.4 Standard control experiment:
采用原儿茶醛、丹酚酸B、隐丹参酮、丹参酮IIA、三七皂苷R1、人参皂苷Rg1、人参皂苷Rb1为参照物,精密称定适量,用70%甲醇溶解,制成标准品溶液,记录色谱图(见图4)。结论:Protocatechualdehyde, salvianolic acid B, cryptotanshinone, tanshinone IIA, notoginsenoside R1, ginsenoside Rg1, and ginsenoside Rb1 were used as reference substances, and an appropriate amount was accurately weighed, dissolved in 70% methanol to prepare a standard solution. Record the chromatogram (see Figure 4). in conclusion:
通过对丹七方供试液制备方法,色谱条件选择及色谱条件方法学研究,确定的现有丹七方色谱分析条件可满足对丹七方中丹参和三七的多类活性成分的同时检测与分析。Through the research on the preparation method of Danqifang's test solution, the selection of chromatographic conditions and the methodology of chromatographic conditions, the determined chromatographic analysis conditions of Danqifang can meet the simultaneous detection of multiple types of active ingredients in Danshen and Panax notoginseng and analyse.
我们将此指纹图谱条件进一步用于含有丹参和三七药材的复方制剂的质量控制。具体如下:We further used this fingerprint condition for the quality control of compound preparations containing Danshen and Panax notoginseng. details as follows:
1.复方丹参制剂的供试液制备:1. Preparation of the test solution of the compound salvia miltiorrhiza preparation:
取丹七片(去糖衣)、复方丹参片和复方丹参滴丸(去除薄膜衣)适量,研成粉末,用70%甲醇溶解并转移到容量瓶中定容。超声提取,放冷,加入70%甲醇补足重量。溶液过0.45μm滤膜,即得。Take an appropriate amount of Danqi Tablets (remove sugar coating), Compound Danshen Tablets and Compound Danshen Dropping Pills (remove film coating), grind into powder, dissolve with 70% methanol and transfer to a volumetric flask to constant volume. Ultrasonic extraction, let cool, add 70% methanol to make up the weight. The solution is obtained by passing through a 0.45 μm filter membrane.
2.用本发明的指纹图谱条件对复方丹参制剂的供试液进行HPLC-DAD色谱分析,即得复方丹参制剂指纹图谱。2. Use the fingerprint conditions of the present invention to carry out HPLC-DAD chromatographic analysis on the test solution of the compound Danshen preparation to obtain the fingerprint of the compound Danshen preparation.
附图说明Description of drawings
图1-1供试品溶液稳定性及仪器精密度实验色谱图(203nm),其中色谱图WDQ00135~WDQ00140分别为0~24小时色谱图Figure 1-1 Experimental chromatograms (203nm) of test solution stability and instrument precision, in which chromatograms WDQ00135~WDQ00140 are 0~24 hours chromatograms respectively
图1-2供试品溶液稳定性及仪器精密度实验色谱图(281nm),其中色谱图WDQ00135~WDQ00140分别为0~24小时色谱图Figure 1-2 Experimental chromatograms (281nm) for the stability of the test product solution and instrument precision, in which the chromatograms WDQ00135~WDQ00140 are the chromatograms of 0~24 hours respectively
图2-1供试品溶液测定的重复性实验色谱图(203nm)The repeatability experiment chromatogram (203nm) that Fig. 2-1 need testing solution measures
图2-2供试品溶液测定的重复性实验色谱图(281nm)The repeatability experiment chromatogram (281nm) that Fig. 2-2 need testing solution measures
图3-1记录时间实验的色谱图(203nm:其中WDQ00120为空白;WDQ00121为供试品)Figure 3-1 Chromatogram of recording time experiment (203nm: where WDQ00120 is blank; WDQ00121 is the test product)
图3-2记录时间实验的色谱图(281nm:其中WDQ00120为空白;WDQ00121为供试品)Figure 3-2 Chromatogram of recording time experiment (281nm: where WDQ00120 is blank; WDQ00121 is the test product)
图4标准品对照试验的色谱图The chromatogram of Fig. 4 standard control test
图5是实施例1中的丹七方指纹图谱Fig. 5 is Dan Qifang fingerprint collection in embodiment 1
图6是实施例2中市售丹七片的指纹图谱Fig. 6 is the fingerprint collection of commercially available Danqi tablets in embodiment 2
图7是实施例3中市售批号为040602的复方丹参片的指纹图谱Fig. 7 is the fingerprint of the Compound Danshen Tablets whose commercially available batch number is 040602 in Example 3
图8是实施例3中市售批号为050308的复方丹参片的指纹图谱Fig. 8 is the fingerprint of the Compound Danshen Tablets whose commercially available batch number is 050308 in Example 3
图9是实施例3中市售批号为03121024的复方丹参片的指纹图谱Fig. 9 is the fingerprint of the Compound Danshen Tablets whose commercially available batch number is 03121024 in Example 3
图10是实施例4中批号为20020921的复方丹参滴丸的指纹图谱Fig. 10 is the fingerprint of the Compound Danshen Dripping Pills whose batch number is 20020921 in Example 4
图11是实施例4中批号为20030604的复方丹参滴丸的指纹图谱Fig. 11 is the fingerprint of the Compound Danshen Dripping Pills whose batch number is 20030604 in Example 4
图12是实施例4中批号为20040303的复方丹参滴丸的指纹图谱Fig. 12 is the fingerprint of the Compound Danshen Dripping Pills whose batch number is 20040303 in Example 4
图13是实施例5中丹七方的指纹图谱。Fig. 13 is the fingerprint of Dan Qifang in Example 5.
图14是实施例5中丹七片的指纹图谱。Fig. 14 is the fingerprint spectrum of Danqi tablets in Example 5.
图15是实施例5中复方丹参片的指纹图谱。Fig. 15 is the fingerprint of Compound Danshen Tablets in Example 5.
图16是实施例5中复方丹参滴丸的指纹图谱。Fig. 16 is the fingerprint of Compound Danshen Dripping Pills in Example 5.
图17是实施例6中丹七片的指纹图谱。Fig. 17 is the fingerprint spectrum of Danqi tablets in Example 6.
图18是实施例6中复方丹参滴丸的指纹图谱。Fig. 18 is the fingerprint of Compound Danshen Dripping Pills in Example 6.
以上附图中各数字表示的是:1.原儿茶醛 2.三七皂苷R1 3.人参皂苷Rg1 4.丹酚酸B 5.人参皂苷Rb1 6.隐丹参酮 7.丹参酮IIAThe numbers in the above drawings represent: 1. Protocatechualdehyde 2.
具体实施方式:Detailed ways:
实施例1Example 1
1实验材料1 Experimental materials
1.1仪器与器材:1.1 Instruments and equipment:
Agilent 1100型系列高效液相色谱仪,包括G1312A四元梯度泵、G1313A自动进样器、G1316A柱温箱,G1315A DAD检测器,HP Chemstation色谱工作站(美国惠谱公司);旋转薄膜蒸发仪(瑞士Büchi公司)。Agilent 1100 series high performance liquid chromatography, including G1312A quaternary gradient pump, G1313A autosampler, G1316A column oven, G1315A DAD detector, HP Chemstation chromatography workstation (U.S. Hewlett-Packard Company); rotary thin film evaporator (Switzerland) Büchi company).
1.2试剂及试药:1.2 Reagents and reagents:
药材:丹参(陕西天士力植物药业有限公司,陕西商洛),经李萍教授鉴定为唇形科植物丹参Salvia miltiorrhiza Bge.的干燥根;三七(云南文山),经李萍教授鉴定为五加科植物三七Panax notoginseng(Burk.)F.H.Chen的干燥根。Medicinal materials: Salvia miltiorrhiza (Shaanxi Tasly Plant Pharmaceutical Co., Ltd., Shangluo, Shaanxi), identified by Professor Li Ping as the dry root of Salvia miltiorrhiza Bge. The dried root of Panax notoginseng (Burk.) F.H.Chen.
2.实验方法2. Experimental method
2.1色谱条件2.1 Chromatographic conditions
色谱柱:C18色谱柱(ZORBAX ODS 4.6×250mm ID,5μm)和C18预柱(4.6×12.5mmID,5μm);柱温:30℃;流动相,A为0.1%的磷酸水;B为乙腈;A+B=100%,采用梯度洗脱:0-10min,7-17%B,10-12min,17-20%B,12-16min,20-21%B,16-32min,21%B,32-40min,21-29%B,40-55min,29-35%B,55-65min,35-70%B,65-75min,70-80%B,75-80min,80-97%B,80-82min,97-100%B,82-85min,100%B;流速:1ml/min(22-28min,0.8ml/min);检测波长203,281nm。记录时间85min。Chromatographic column: C18 chromatographic column (ZORBAX ODS 4.6×250mm ID, 5μm) and C18 pre-column (4.6×12.5mmID, 5μm); column temperature: 30°C; mobile phase, A is 0.1% phosphoric acid water; B is acetonitrile; A+B=100%, gradient elution: 0-10min, 7-17%B, 10-12min, 17-20%B, 12-16min, 20-21%B, 16-32min, 21%B, 32-40min, 21-29%B, 40-55min, 29-35%B, 55-65min, 35-70%B, 65-75min, 70-80%B, 75-80min, 80-97%B, 80-82min, 97-100%B, 82-85min, 100%B; flow rate: 1ml/min (22-28min, 0.8ml/min); detection wavelength 203, 281nm. The recording time is 85min.
2.2供试品溶液的制备2.2 Preparation of the test solution
取粉碎的丹参1.2g,三七1.2g,加入90%乙醇25ml,浸泡1h,水浴回流提取2h,放冷,滤过;药渣加40ml水继续煎煮2h,滤过,合并滤液,于50℃减压回收乙醇至干,加70%甲醇溶解并转移至100ml容量瓶定容至刻度,微孔滤膜过滤,得供试品溶液。Take crushed salvia miltiorrhiza 1.2g, panax notoginseng 1.2g, add 25ml of 90% ethanol, soak for 1h, reflux in a water bath for 2h, let cool, and filter; add 40ml of water to the dregs and continue to decoct for 2h, filter, combine the filtrate, and put in 50 Recover ethanol under reduced pressure at ℃ to dryness, add 70% methanol to dissolve and transfer to a 100ml volumetric flask to set the volume to the mark, and filter through a microporous membrane to obtain the test solution.
3.实验结果:将供试品溶液进样10μl进行色谱分析,即得丹七方指纹图谱,记录时间为85min。见图5。3. Experimental results: 10 μl of the test solution was injected for chromatographic analysis, and the fingerprint of Dan Qifang was obtained, and the recording time was 85 minutes. See Figure 5.
实施例2Example 2
取市售丹七片(湖南安邦制药有限责任公司,批号:040803)20片,去糖衣并研磨成粉末,精密称取0.5g,置25ml棕色容量瓶中,70%甲醇定容。超声提取30min,放冷,加入70%甲醇补足重量。溶液过0.45μm滤膜。其它条件同实施例1。进样10μl进行色谱分析,得丹七片HPLC-DAD指纹图谱,见图6。Take 20 commercially available Danqi Tablets (Hunan Anbang Pharmaceutical Co., Ltd., batch number: 040803), remove the sugar coating and grind them into powder, accurately weigh 0.5g, put in a 25ml brown volumetric flask, and dilute to volume with 70% methanol. Ultrasonic extraction was performed for 30 min, allowed to cool, and 70% methanol was added to make up the weight. The solution was passed through a 0.45 μm membrane filter. Other conditions are with embodiment 1. Inject 10 μl of sample for chromatographic analysis, and get the HPLC-DAD fingerprint of seven tablets of Dandan, as shown in Figure 6.
实施例3Example 3
取市售复方丹参片(广东白云山制药厂,批号:03121024;南京同仁堂制药有限责任公司,批号:040602:浙江胡庆余堂制药有限责任公司,批号:050308)20片,研磨成粉未,精密称取0.5g,置25ml棕色容量瓶中,70%甲醇定容。超声提取30min,放冷,加入70%甲醇补足重量。溶液过0.45μm滤膜。其它条件同实施例1。进样10μl进行色谱分析,得3个厂家复方丹参片HPLC-DAD指纹图谱,见图7-9。Get commercially available Compound Danshen Tablets (Guangdong Baiyunshan Pharmaceutical Factory, batch number: 03121024; Nanjing Tongrentang Pharmaceutical Co., Ltd., batch number: 040602; Zhejiang Huqing Yutang Pharmaceutical Co., Ltd., batch number: 050308) 20 tablets, ground into powder, and accurately weighed Take 0.5g, put it in a 25ml brown volumetric flask, and dilute to volume with 70% methanol. Ultrasonic extraction was performed for 30 min, allowed to cool, and 70% methanol was added to make up the weight. The solution was passed through a 0.45 μm membrane filter. Other conditions are with embodiment 1. Inject 10 μl of sample for chromatographic analysis, and obtain the HPLC-DAD fingerprints of Compound Danshen Tablets from three manufacturers, as shown in Figure 7-9.
实施例4Example 4
取市售复方丹参滴丸(天津天士力制药有限责任公司,批号:20020921,20030604,20040303)75粒,精密称定,研成粉未,去除薄膜衣,用70%甲醇溶解并转移到25ml棕色容量瓶中定容。超声提取30min,放冷,加入70%甲醇补足重量。溶液过0.45μm滤膜。其它条件同实施例1。进样10μl进行色谱分析,得3个批号复方丹参滴丸的HPLC-DAD指纹图谱。见图10-12。Get 75 commercially available compound danshen dripping pills (Tianjin Tasly Pharmaceutical Co., Ltd., batch number: 20020921, 20030604, 20040303), accurately weighed, grind into powder, remove film coat, dissolve with 70% methanol and transfer to 25ml brown capacity Make up to volume in the bottle. Ultrasonic extraction was performed for 30 min, allowed to cool, and 70% methanol was added to make up the weight. The solution was passed through a 0.45 μm membrane filter. Other conditions are with embodiment 1. Inject 10 μl for chromatographic analysis, and obtain the HPLC-DAD fingerprints of 3 batches of Compound Danshen Dripping Pills. See Figure 10-12.
实施例5Example 5
用上述实施例同样的方法,只是将洗脱梯度改为55分钟后:55-65min,35-65%B,65-80min,65-80%B,80-85min,80-100%B。分别对丹七方,丹七片,复方丹参片(广东白云山制药厂,批号:03121024)及复方丹参滴丸(天津天士力制药有限责任公司,批号:20020921)进行色谱分析,得指纹图谱见图13-16。Use the same method as the above example, but change the elution gradient to 55 minutes later: 55-65min, 35-65%B, 65-80min, 65-80%B, 80-85min, 80-100%B. Chromatographic analysis was carried out on Danqifang, Danqi Tablets, Compound Danshen Tablets (Guangdong Baiyunshan Pharmaceutical Factory, batch number: 03121024) and Compound Danshen Dripping Pills (Tianjin Tasly Pharmaceutical Co., Ltd., batch number: 20020921), and the fingerprints are shown in the figure 13-16.
实施例6Example 6
用实施例1、2、4的方法,只是记录时间改为60分钟,分别对丹七片和复方丹参滴丸(天津天士力制药有限责任公司,批号:20020921)进行色谱分析。得指纹图谱见图17-18。With the method of Example 1, 2, 4, only the recording time was changed to 60 minutes, and the chromatographic analysis was carried out to Danqi Tablets and Compound Danshen Dripping Pills (Tianjin Tasly Pharmaceutical Co., Ltd., batch number: 20020921) respectively. The obtained fingerprints are shown in Figure 17-18.
综上,本发明所建立的丹参和三七复方的HPLC-DAD指纹图谱可用于同时检测丹参中丹酚酸B等酚酸类水溶性成分和丹参酮IIA等二萜醌类脂溶性成分以及三七中皂苷类成分,方法可靠、稳定,可用于含有丹参和三七的复方制剂的质量控制。In summary, the HPLC-DAD fingerprints of the Danshen and Panax notoginseng compound established in the present invention can be used to simultaneously detect the water-soluble components of phenolic acids such as salvianolic acid B and the lipid-soluble components of diterpene quinones such as tanshinone IIA and Panax notoginseng The composition of saponins is reliable and stable, and it can be used for quality control of compound preparations containing Danshen and Panax notoginseng.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100951807A CN100360931C (en) | 2005-11-02 | 2005-11-02 | A kind of quality control method of salvia miltiorrhiza and notoginseng preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100951807A CN100360931C (en) | 2005-11-02 | 2005-11-02 | A kind of quality control method of salvia miltiorrhiza and notoginseng preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1806819A CN1806819A (en) | 2006-07-26 |
CN100360931C true CN100360931C (en) | 2008-01-09 |
Family
ID=36839029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100951807A Expired - Fee Related CN100360931C (en) | 2005-11-02 | 2005-11-02 | A kind of quality control method of salvia miltiorrhiza and notoginseng preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100360931C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101912440B (en) * | 2010-08-06 | 2012-12-12 | 广州白云山和记黄埔中药有限公司 | Quality control method of complex salvia tablet and application thereof |
CN108333282A (en) * | 2018-04-24 | 2018-07-27 | 山东农业大学 | A kind of method of a variety of phenolic acid class and tanshinone component in Rapid Simultaneous Determination Fufang Danshen Pian |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1669573A (en) * | 2004-03-17 | 2005-09-21 | 天津天士力制药股份有限公司 | Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and preparing process thereof |
-
2005
- 2005-11-02 CN CNB2005100951807A patent/CN100360931C/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1669573A (en) * | 2004-03-17 | 2005-09-21 | 天津天士力制药股份有限公司 | Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and preparing process thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1806819A (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | A review of traditional Chinese medicine on treatment of diabetic nephropathy and the involved mechanisms | |
CN108226321B (en) | Fingerprint detection method and fingerprint of fructus piperis longi and fructus piperis longi stomach-ache granules | |
CN101485705A (en) | Cooked Panax notoginseng and cooked Panax notoginseng standard extract and application thereof | |
CN101816773B (en) | Method for measuring content of superfine powder preparation in five retentions powder | |
CN102353735B (en) | Quality detection method for Tongmai Tangyanming capsule | |
CN108037193B (en) | Method for detecting compound salvia miltiorrhiza tablets by adopting HP L C-UV-E L SD method | |
CN107860832A (en) | The method for building up of compound rubarb Qi Yi Tang finger-print | |
CN110763793A (en) | Method for detecting active ingredients of salvia miltiorrhiza and products | |
CN108295102A (en) | A kind of moringa oleifera leaf extractive and extracting method with Lipid-lowering activities | |
CN108997469A (en) | A kind of jujube root extract, extraction separation method and its application | |
Dong et al. | Orthogonal array design in optimizing the extraction efficiency of active constituents from roots of Panax notoginseng | |
CN100543469C (en) | The detection method of Shiquandabu Gao | |
Wei et al. | Simultaneous determination of seven active components of Fufang Danshen tablet by high performance liquid chromatography | |
CN103487548A (en) | Method for detecting Jinma Gantai preparation for treating hepatitis | |
CN100360931C (en) | A kind of quality control method of salvia miltiorrhiza and notoginseng preparation | |
Zheng et al. | Research progress on the pharmacological mechanisms of Chinese medicines that tonify Qi and activate blood against cerebral ischemia/reperfusion injury | |
CN102100737B (en) | Medicinal composition containing general ginsenoside and total salvianolic acid and preparation method thereof | |
CN103969353B (en) | A kind of discrimination method of finger-print of rheum officinale Salvia root P.E | |
CN103969356B (en) | A kind of discrimination method of the finger printing of red rooted salvia | |
CN112946118B (en) | Method for measuring medicine fingerprint and fingerprint thereof | |
Yan et al. | Simultaneous quantification of a herbal combination of Pueraria lobata, Salvia miltiorrhiza and Panax notoginseng by rapid resolution liquid chromatography | |
Liu et al. | Simultaneous Determination and Pharmacokinetic Comparisons of Multi‐Ingredients after Oral Administration of Radix Salviae Miltiorrhizae Extract, Hawthorn Extract, and a Combination of Both Extracts to Rats | |
Liu et al. | Chemical composition differentiation of Shen‐Shuai‐Ning granule between combined decoction and separated decoction using HPLC‐DAD‐ESI‐QTOF‐MS | |
Yokozawa et al. | Effect of traditional chinese prescriptions and their main crude drugs on 1, 1‐diphenyl‐2‐picrylhydrazyl radical | |
Luo et al. | Optimized isolation and purification of Shaoyao Gancao decoction using macroporous resin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080109 Termination date: 20091202 |